Simulect induction facilitates neoral-based steroid-free immunosuppression in primary kidney transplant recipients

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S475-S477

  Kung, S C ^a,b   Parikh, M ^b   Fyfe, B ^a,b   Xiao, S G ^a   Sierka, D ^a   Heifets, M ^a,b   Moritz, M ^a,b   Anil Kumar, M S ^a,b,c  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b DREXEL UNIVERSITY   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERMETHOD COMPARISON; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RISK REDUCTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 1642401483     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.049     Document Type: Article

References (7)

1. Ponticelli C., Civati G., Tarantino A., et al. Randomized study with cyclosporine in kidney transplantation: 10 year follow-up. J Am Soc Nephrol. 7:1996;792.
2. Pollard S.G., Lear P.A., Ready A.R., et al. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group. Transplantation. 68:1999;1325.
3. Kirkman R.L., Shapiro M.E., Carpenter C.B., et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation. 51:1991;107.
4. Soulillou J.P., Cantarovich D., Le Mauff B., et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med. 322:1990;1175.
5. Kahan B.D., Rajagopalan P.R., Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 67:1999;276.
6. Ponticelli C., Yussim A., Cambi V., et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation. 72:2001;1261.
7. Cockcroft D., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31.